High expression levels of erythropoietin and its receptor are not correlated with shorter survival in human glioblastoma

Brunotte,J.; Bock,H. C.; Brück,W.; Hemmerlein,B.; Strik,H.

doi:10.3892/etm.2011.198

High expression levels of erythropoietin and its receptor are not correlated with shorter survival in human glioblastoma

Authors:
- J. Brunotte
- H. C. Bock
- W. Brück
- B. Hemmerlein
- H. Strik
View Affiliations

Affiliations: Department of Neurology, University Medicine Göttingen, Göttingen, Germany, Department of Neurosurgery, University Medicine Göttingen, Göttingen, Germany, Department of Neuropathology, University Medicine Göttingen, Göttingen, Germany, Department of Pathology, University Medicine Göttingen, Göttingen, Germany, Department of Neurology, University of Marburg, D-35039 Marburg, Germany
Published online on: January 19, 2011 https://doi.org/10.3892/etm.2011.198
Pages: 295-299

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Erythropoietin (EPO) is used to treat anemia in neoplastic disease. EPO also exerts neuroprotective effects on neuronal cells, making a prophylactic use against the neurocognitive effects of radiochemotherapy probable. However, EPO/EPO-receptor (EPOR) signalling has been also detected in glioblastoma cells. Data collected in vitro and in vivo show conflicting results on the effect of EPO on malignant gliomas. The association between EPO and EPOR expression and the prognosis of human glioblastomas was analyzed. Probes of human glioblastomas with complete documentation of clinical course and treatment were assessed by immunohistochemistry for the expression of EPO and EPOR (n=80). Using univariate and multivariate survival analysis, the association with age, gender, radiation, chemotherapy and extent of resection was determined. High levels of EPOR were correlated with a median survival advantage of 7 months (p<0.01). By univariate, but not multivariate, analysis, high levels of EPO and EPOR were associated with a significant prolongation of 7 months median survival when compared to low levels of both molecules. In patients treated with radiochemotherapy adjuvant to surgery, the median survival was 6.5 months longer in patients with high levels of EPOR (p<0.04). According to previous studies, longer patient survival is associated with EPOR expression. Therefore, EPO appears to be safe for the treatment of anemia in glioblastoma patients. Ηowever, a prophylactic use, i.e., for neuroprotection, is not recommended in light of the functional studies described in the literature.

View Figures

View References

1.	Davis FG, McCarthy BJ, Freels S, Kupelian V and Bondy ML: The conditional probability of survival of patients with primary malignant brain tumors: surveillance, epidemiology, and end results (SEER) data. Cancer. 85:485–491. 1999. View Article : Google Scholar : PubMed/NCBI
2.	Stupp R, Mason WP, van den Bent MJ, et al: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 352:987–996. 2005. View Article : Google Scholar : PubMed/NCBI
3.	Erbayraktar S, de Lanerolle N, de Lotbiniere A, et al: Carbamylated erythropoietin reduces radiosurgically-induced brain injury. Mol Med. 12:74–80. 2006. View Article : Google Scholar : PubMed/NCBI
4.	Mulcahy L: The erythropoietin receptor. Semin Oncol. 28:19–23. 2001. View Article : Google Scholar
5.	Sasaki R, Masuda S and Nagao M: Erythropoietin: multiple physiological functions and regulation of biosynthesis. Biosci Biotechnol Biochem. 64:1775–1793. 2000. View Article : Google Scholar : PubMed/NCBI
6.	Leyland-Jones B: Evidence for erythropoietin as a molecular targeting agent. Semin Oncol. 29:145–154. 2002. View Article : Google Scholar : PubMed/NCBI
7.	Nakamura Y, Komatsu N and Nakauchi H: A truncated erythropoietin receptor that fails to prevent programmed cell death of erythroid cells. Science. 257:1138–1141. 1992. View Article : Google Scholar : PubMed/NCBI
8.	Khan FA, Shukla AN and Joshi SC: Anaemia and cancer treatment: a conceptual change. Singapore Med J. 49:759–764. 2008.PubMed/NCBI
9.	Smith RE Jr: Erythropoietic agents in the management of cancer patients. Part 2: studies on their role in neuroprotection and neurotherapy. J Support Oncol. 2:39–49. 2004.PubMed/NCBI
10.	Berdel WE, Oberberg D, Reufi B and Thiel E: Studies on the role of recombinant human erythropoietin in the growth regulation of human nonhematopoietic tumor cells in vitro. Ann Hematol. 63:5–8. 1991. View Article : Google Scholar
11.	Mohyeldin A, Dalgard CL, Lu H, et al: Survival and invasiveness of astrocytomas promoted by erythropoietin. J Neurosurg. 106:338–350. 2007. View Article : Google Scholar : PubMed/NCBI
12.	Molls M, Stadler P, Becker A, Feldmann HJ and Dunst J: Relevance of oxygen in radiation oncology. Mechanisms of action, correlation to low hemoglobin levels. Strahlenther Onkol. 174:13–16. 1998.PubMed/NCBI
13.	Kelleher DK, Mattheinsen U, Thews O and Vaupel P: Blood flow, oxygenation, and bioenergetic status of tumors after erythropoietin treatment in normal and anemic rats. Cancer Res. 56:4728–4734. 1996.PubMed/NCBI
14.	Brizel DM, Sibley GS, Prosnitz LR, Scher RL and Dewhirst MW: Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck. Int J Radiat Oncol Biol Phys. 38:285–289. 1997. View Article : Google Scholar : PubMed/NCBI
15.	Höckel M, Schlenger K, Aral B, Mitze M, Schaffer U and Vaupel P: Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res. 56:4509–4515. 1996.PubMed/NCBI
16.	Ning S, Hartley C, Molineux G and Knox SJ: Darbepoietin alpha potentiates the efficacy of radiation therapy in mice with corrected or uncorrected anemia. Cancer Res. 65:284–290. 2005.PubMed/NCBI
17.	Pinel S, Barberi-Heyob M, Cohen-Jonathan E, Merlin JL, Delmas C, Plenat F and Chastagner P: Erythropoietin-induced reduction of hypoxia before and during fractionated irradiation contributes to improvement of radioresponse in human glioma xenografts. Int J Radiat Oncol Biol Phys. 59:250–259. 2004. View Article : Google Scholar
18.	Thews O, Koenig R, Kelleher DK, Kutzner J and Vaupel P: Enhanced radiosensitivity in experimental tumours following erythropoietin treatment of chemotherapy-induced anaemia. Br J Cancer. 78:752–756. 1998. View Article : Google Scholar : PubMed/NCBI
19.	Westphal G, Niederberger E, Blum C, et al: Erythropoietin and G-CSF receptors in human tumor cells: expression and aspects regarding functionality. Tumori. 88:150–159. 2002.PubMed/NCBI
20.	Hassouna I, Sperling S, Kim E, et al: Erythropoietin augments survival of glioma cells after radiation and temozolomide. Int J Radiat Oncol Biol Phys. 72:927–934. 2008. View Article : Google Scholar : PubMed/NCBI
21.	Mittelbronn M, Capper D, Bunz B, et al: De novo erythropoietin receptor (EPO-R) expression in human neoplastic glial cells decreases with grade of malignancy but is favourably associated with patient survival. Neuropathol Appl Neurobiol. 33:299–307. 2007. View Article : Google Scholar
22.	Henke M, Laszig R, Rube C, et al: Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet. 362:1255–1260. 2003. View Article : Google Scholar
23.	Leyland-Jones B, Semiglazov V, Pawlicki M, et al: Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study. J Clin Oncol. 23:5960–5972. 2005. View Article : Google Scholar
24.	Bohlius J, Wilson J, Seidenfeld J, et al: Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients. J Natl Cancer Inst. 98:708–714. 2006. View Article : Google Scholar : PubMed/NCBI